Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  US Nuclear Corp.    UCLE

US NUCLEAR CORP.

(UCLE)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

US Nuclear Joins the Brain-Machine Interface Revolution

02/11/2020 | 08:31am EST

Los Angeles, CA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- US Nuclear Corp. (OTC: UCLE) recently signed a stock purchase agreement with start-up Grapheton Inc. to acquire a 40% stake in the company.  

Similar to Elon Musk’s ‘Neuralink’, Grapheton is developing and manufacturing an advanced new generation of wearable and implantable brain-machine interface devices. Grapheton’s long-term goal is dedicated specifically to treating injuries and disease such as spinal injuries, pain reduction, Parkinson’s Disease, epilepsy, stroke, and possibly Alzheimer’s.  Grapheton already has several pivotal and patented advantages in the field, including: 

  1. Grapheton’s electrodes utilize a new carbon-based material that doesn’t corrode and can last as long as 40 years or more compared to less than five years from other providers, which is extremely important considering the invasive surgery required for installation or maintenance of the probes.  
  2. Self-charging supercapacitor which uses the brain’s own salty liquid environment as the power source, meaning that unlike other providers, no battery maintenance is required to reinstall a new battery while also ensuring that aging batteries will not leak any chemicals into the brain.  Again, a huge advantage for reducing the surgery and maintenance required.  
  3. Two-way electrical and chemical communication with brain neurons, meaning that Grapheton’s probes can not only send electrical signals, but also listen, record, and respond to the body’s electrical and chemical signals simultaneously.  

Grapheton’s products are already in use at various research centers and currently include: ECoG probes (electrocorticography- monitoring the electrical activity of the brain), spinal stimulation probes for spinal injuries, brain chemical sensors, surface electrodes for MRIs, and other micro-electrode arrays and electrochemical sensors.  US Nuclear will provide systems engineering, manufacturing, and marketing support to help Grapheton leverage their unique patented advantages and make these products commercially available to all people who can benefit from them.  US Nuclear’s monetary support will also enable Grapheton to research and develop new and exciting brain-machine interface products.    

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com.

CONTACT:

US Nuclear Corp. (OTCBB: UCLE)

Robert I. Goldstein, President, CEO, and Chairman 

Rachel Boulds, Chief Financial Officer

(818) 883 7043

Email: info@usnuclearcorp.com

Primary Logo


© GlobeNewswire 2020
All news about US NUCLEAR CORP.
01/06US NUCLEAR CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06US NUCLEAR : 2019 Convertible Debenture Now Fully Converted, Closed, and Flat
AQ
2020US Nuclear Corp. Discusses The Progress of Its MIFTEC Contract and Overhuff T..
NE
2020US Nuclear Corp. Announces Third Quarter 2020 Results
GL
2020US NUCLEAR : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2020US NUCLEAR : and Grapheton Brain Implants to Help Immobilized Patients
AQ
2020US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
GL
2020US NUCLEAR : Secures Its Position at Bioelectronics Startup Grapheton
AQ
2020US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
GL
2020US NUCLEAR : Tritium Monitor Market Soars Due to Construction of $20+ Billion IT..
AQ
More news
Financials (USD)
Sales 2019 3,54 M - -
Net income 2019 -3,16 M - -
Net cash 2019 0,10 M - -
P/E ratio 2019 -4,28x
Yield 2019 -
Capitalization 7,41 M 7,41 M -
EV / Sales 2018 2,02x
EV / Sales 2019 3,85x
Nbr of Employees 20
Free-Float 48,4%
Chart US NUCLEAR CORP.
Duration : Period :
US Nuclear Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert I. Goldstein Chairman, President & Chief Executive Officer
Richard Landry COO & Director-Investor Relations
Rachel Boulds Chief Financial Officer & Secretary
Michael G. Hastings Director
Dell Williamson Director
Sector and Competitors